AbbVie Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert A. Michael
- Full Time Employees
- 55,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 1 North Waukegan Road North Chicago IL United States of America 60064-6400
- IPO Date
- Jan 2, 2013
- CIK
- 0001551152
- Website
- abbvie.com
- Similar Companies
- Business
- AbbVie Inc. (NYSE: ABBV) is a global research-based biopharmaceutical company that discovers, develops, manufactures and commercializes innovative medicines across immunology, oncology, neuroscience, eye care, aesthetics, virology and gastroenterology. Founded in 2013 as a spin-off from Abbott Laboratories and headquartered in North Chicago, Illinois, the company operates in more than 70 countries with approximately 55,000 employees worldwide. Its core products include Humira (adalimumab) for autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease and ulcerative colitis; Skyrizi (risankizumab) and Rinvoq (upadacitinib), both interleukin inhibitors for immunology indications; Imbruvica (ibrutinib) and Venclexta (venetoclax) for oncology; Vraylar (cariprazine) for schizophrenia and bipolar disorder; Botox for aesthetics; Mavyret (glecaprevir/pibrentasvir) for hepatitis C; and Epkinly (epcoritamab) for blood cancers, among others including Duopa/Duodopa, Ubrelvy and Vyalev in neuroscience and pipeline candidates for Parkinson's disease. AbbVie markets its portfolio to patients, healthcare providers and health systems globally, with major revenue contributions from the United States and international markets. In recent developments, the company completed acquisitions of ImmunoGen for $10.1 billion in 2024 to bolster ovarian cancer treatments with Elahere, Cerevel Therapeutics for $8.7 billion to expand neuroscience, Aliada Therapeutics for $1.4 billion, Nimble Therapeutics and Capstan Therapeutics in 2024-2025 for immunology enhancements, and Gilgamesh Pharmaceuticals in 2025 for a psychiatry drug bretisilocin valued up to $1.2 billion; it also announced partnerships such as $1.64 billion with Neomorph for molecular glue degraders and licensing from Gubra for obesity treatments, alongside over 30 deals since 2024 and manufacturing expansions including a $195 million API facility and $70 million biologics site in the U.S. to support over $10 billion in domestic investments.
Johnson & Johnson vs AbbVie: Two Paths to Pharma Dominance, One Winner
AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note
WST Completes SmartDose Sale to AbbVie to Focus on Core Growth
Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma
Buy these quality, low-stress stocks for the summer, says Jefferies
3 High-Yield Dividend Stocks to Buy and Hold Forever (Hint: AbbVie Makes the List)
3 Dividend Aristocrats to Buy in July
The Dividend ETF Quietly Outperforming the S&P 500
AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
Will Immunology Franchise Aid AbbVie's Upcoming Q2 Results?
Social Security Pays $2,081 a Month. Here’s How Much You Need Invested to Match It.
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?
J&J or AbbVie: Which Stock Deserves a Place in Your Portfolio Now?
3 Dividend Stocks to Buy Hand Over Fist in July
AbbVie: Apogee Deal Just Widened An Already Dominant Moat
This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy?
What Sparked the $43B Jump in AbbVie's Market Cap in the Past Week?
Merck, AbbVie probed by US lawmakers over China clinical trials: report
Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity